Tolerance to factor VIII in the era of nonfactor therapies: immunologic perspectives and a systematic review of the literature

This publication has 64 references indexed in Scilit:

• Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)
  Research and Practice in Thrombosis and Haemostasis, 2024
• Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
  Research and Practice in Thrombosis and Haemostasis, 2023
• Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study
  The Lancet Haematology, 2023
• Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort
  Journal of Thrombosis and Haemostasis, 2023
• Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status
  Research and Practice in Thrombosis and Haemostasis, 2021
• Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
  The Lancet Haematology, 2019
• Recognition of coagulation factor VIII by CD4+ T cells of healthy humans
  Journal of Thrombosis and Haemostasis, 2003
• Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review
  Haemophilia, 2003
• Inhibitor development in correlation to factor VIII genotypes
  Haemophilia, 2002
• Characterization of Antibodies Induced by Human Factor VIII in a Murine Knockout Model of Hemophilia A
  Thrombosis and Haemostasis, 2000